Peak Resources (PEK.ASX)
Company Info
PEK has a market cap of $42m, with $8.3m in cash and a cash burn of around $3m/quarter.
Ngualla Deposit
Project stats are listed at the bottom. Main thoughts on the project are as follows:
- It’s a light REE deposit with a less favorable distribution of REEs (refer scoping study page 14). This will reduce its chance of attracting buyers or JV partners, and I think it will struggle to gain traction with other low cost, high volume LREE facilities now entering production.
- To their credit, they have made good progress in 2012, but it remains a very early stage project. Every well-developed REE project has taken years of process development and this project has a long way to go - despite the optimistic target of a Q1 2016 startup.
-The deposit size is large at 3.8Mt of contained REO, but only a portion of this (likely 1-1.5mt) belongs to the Bastnaesite Zone. The remainder belongs to the Monazite Zone which is harder to process and mostly a lower grade. At this stage I wouldn't attribute much value to the REO in Monazite zone.
- Concentrate grade is too low at 7%. Its early days so one expects they will improve this, but a light REE project like this one needs a high REE concentrate grade to allow it compete with Lynas and Moly.
- Other than GGG, it is the only REE project I can recall that cracks the concentrate via atmospheric leaching. This will help reduce refining costs.
- The 10ktpa of product is made up of 3.65ktpa of cerium oxide concentrate (low value) and 6.35ktpa of partly separated REO.
- Project NPV looks attractive, but the inputs look very optimistic. For example, they state the capital cost as $400m + contingency (and note that a 35% contingency is normally relevant), then appear to use $400m in the NPV calculation. I also would have liked to see a lower basket price used given approaching market oversupply in La and Ce, and the fact that some products aren’t fully separated.
- I am concerned at the apparent "marketing spin" in the company announcements, particularly the scoping study - which should be an unbiased evaluation of the project. I guess this is understandable given the future capital requirements, but I much prefer to see an "under promise, over deliver" management approach.
At an enterprise value of $34m one could make a case of value, and process breakthroughs could turn it into a viable project. But its a risky prospect IMO.
Ngualla Project Stats
Project Stage: Scoping Study recently finished
In-situ grade: Good – 4.35% (high grade part only)
Deposit size: Large, 3.8mt of contained REO @
HREEs: Low
Extraction costs: Low – near surface
REO Conc grade: Low – approx. 6.4%
Ease of refining: Looks reasonable, but early stage
Saleable by-products: Not significant
Undesirable by-products: Low with in country processing
Capacity: Small <10ktpa
Opex: Quoted at $11/kg in scoping study, but I'm suspect on the numbers.
Capex: $400m + contingency. Some cost components seem low compared to other projects.
Process Risk: Very high at scoping stage
Country / Political Risk: Low as can be expected in Africa
Off-takes: None
- Forums
- ASX - By Stock
- ETM
- ree projects
ree projects, page-20
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ETM (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.58M |
Open | High | Low | Value | Volume |
2.1¢ | 2.1¢ | 2.0¢ | $19.58K | 966.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 775714 | 2.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.1¢ | 139369 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 775714 | 0.020 |
3 | 1370000 | 0.019 |
2 | 946590 | 0.018 |
1 | 1078254 | 0.017 |
2 | 1480386 | 0.016 |
Price($) | Vol. | No. |
---|---|---|
0.021 | 139369 | 1 |
0.022 | 829344 | 1 |
0.024 | 400000 | 1 |
0.025 | 600000 | 2 |
0.026 | 15000 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
ETM (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online